Sugi Predict

Sugi Predict / Compounds / SCHEMBL2588056

SCHEMBL2588056

SCHEMBL2588056

COC(=O)c1cc(Br)cc2c1cnn2C(C)C

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ EZH2 Q15910 3/20 0.48
▸ KDM4E B2RXH2 2/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ CYP11B2 P19099 1/20 0.38
▸ P2RX3 P56373 1/20 0.38
▸ P2RX2 Q9UBL9 1/20 0.38
▸ PDE1A P54750 1/20 0.37
▸ PDE1B Q01064 1/20 0.37
▸ PDE1C Q14123 1/20 0.37
▸ OPRK1 P41145 6/20 0.37
▸ IRAK4 Q9NWZ3 2/20 0.37
▸ EED O75530 1/20 0.36
▸ RBBP4 Q09028 1/20 0.36
▸ SUZ12 Q15022 1/20 0.36
▸ RBBP7 Q16576 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ NR4A2 P43354 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31474829 1.00 EZH2 (0.48) EZH2KDM4EL3MBTL1CYP11B2P2RX3
SCHEMBL31474839 0.85 KDM4E (0.53) EZH2KDM4EP2RX3P2RX2PDE1A
SCHEMBL2588942 0.85 KDM4E (0.53) EZH2KDM4EP2RX3P2RX2PDE1A
SCHEMBL12180709 0.84 KDM4E (0.39) EZH2KDM4EL3MBTL1CYP11B2P2RX3
SCHEMBL2594697 0.84 PDE1A (0.40) EZH2KDM4ECYP11B2P2RX3P2RX2
SCHEMBL2594144 0.84 EZH2 (0.40) EZH2KDM4ECYP11B2P2RX3P2RX2
SCHEMBL456891 0.82 CYP1A2 (0.42) L3MBTL1CYP11B2PDE1COPRK1IRAK4
SCHEMBL2594991 0.80 PDE1A (0.37) EZH2KDM4EL3MBTL1CYP11B2P2RX3
SCHEMBL2594905 0.80 CREBBP (0.43) EZH2KDM4EL3MBTL1CYP11B2OPRK1
SCHEMBL12499367 0.80 CREBBP (0.42) L3MBTL1CYP11B2OPRK1IRAK4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119409682-A 1H-indazole compound and preparation method and application thereof 南京健康产业研究院 2025-02-11 — — CN disclosed
US-12144816-B2 Substituted indole Mcl-1 inhibitors VANDERBILT UNIVERSITY (US) 2024-11-19 — — US disclosed
CN-118745144-A Novel EZH2 inhibitor compound, and preparation method and application thereof 辽宁大学 2024-10-08 — — CN disclosed
EP-4292662-A2 SUBSTITUTED INDOLE MCL-1 INHIBITORS Vanderbilt University (US) 2023-12-20 — — EP disclosed
US-20230330099-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS VANDERBILT UNIVERSITY 2023-10-19 — — US disclosed
EP-3423435-B1 SUBSTITUTED INDOLE MCL-1 INHIBITORS UNIV VANDERBILT (US) 2023-08-23 — — EP disclosed
EP-3323820-B1 SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS EPIZYME INC (US) 2023-05-10 — — EP disclosed
US-11596639-B2 Substituted indole Mcl-1 inhibitors VANDERBILT UNIVERSITY (US) 2023-03-07 — — US disclosed
CN-109153643-B Substituted indole MCL-1 inhibitors 范德比尔特大学 2022-06-21 — — CN disclosed
US-20210283138-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS VANDERBILT UNIVERSITY 2021-09-16 — — US disclosed
US-8598167-B1 Substituted 6,5-fused bicyclic heteroaryl compounds Epizyme, Inc. (US) 2013-12-03 — — US disclosed
US-20130317026-A1 SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS Epizyme, Inc. (US) 2013-11-28 — — US disclosed
WO-2013067300-A1 METHOD OF TREATMENT GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2013-05-10 — — WO disclosed
EP-2566328-A1 INDAZOLES GlaxoSmithKline LLC (US) 2013-03-13 — — EP disclosed
US-20130053383-A1 INDAZOLES GLAXOSMITHKLINE LLC 2013-02-28 — — US disclosed
US-20130053383-A1 INDAZOLES GLAXOSMITHKLINE LLC 2013-02-28 — — US disclosed
US-20130053383-A1 INDAZOLES GLAXOSMITHKLINE LLC 2013-02-28 — — US disclosed
WO-2012118812-A2 SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS Epizyme, Inc. (US) 2012-09-07 — — WO disclosed
WO-2011140325-A1 INDAZOLES GLAXOSMITHKLINE LLC (US) 2011-11-10 — — WO disclosed
WO-2011140325-A1 INDAZOLES GLAXOSMITHKLINE LLC (US) 2011-11-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210283138-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, BCL9 EZH2 296/4885KDM4E 1156/4885L3MBTL1 135/4885
US-20130053383-A1 INDAZOLES IDH3A, CYP3A7, IDH3B EZH2 1599/4885KDM4E 2573/4885L3MBTL1 2754/4885
US-12144816-B2 Substituted indole Mcl-1 inhibitors MCL1, BCL2L1, BCL9 EZH2 296/4885KDM4E 1156/4885L3MBTL1 135/4885
US-20230330099-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, BCL9 EZH2 296/4885KDM4E 1156/4885L3MBTL1 135/4885
US-20130317026-A1 SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2D6 EZH2 1355/4885KDM4E 1279/4885L3MBTL1 3900/4885
US-11596639-B2 Substituted indole Mcl-1 inhibitors MCL1, BCL2L1, BCL9 EZH2 296/4885KDM4E 1156/4885L3MBTL1 135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.